問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

Recruiting Trial

767Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1613Cases

2023-08-01 - 2024-10-30

Phase III

CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

  • Condition/Disease

    Autosomal Dominant Hypocalcemia (ADH)

  • Test Drug

    Encaleret

Participate Sites
1Sites

Recruiting1Sites

2019-03-26 - 2023-02-06

Phase III

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

  • Condition/Disease

    Immunoglobulin A nephropathy

  • Test Drug

    Nefecon™

Participate Sites
3Sites

Recruiting3Sites

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

  • Condition/Disease

    advanced stage hepatocellular carcinoma

  • Test Drug

    Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2020-03-01 - 2022-12-30

Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

  • Condition/Disease

    Advanced/Metastatic solid tumors

  • Test Drug

    V941 (mRNA-5671)/ Pembrolizumab

Participate Sites
3Sites

Recruiting3Sites

2020-10-01 - 2023-11-21

Phase II

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    MK-3655

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated3Sites

2014-10-01 - 2020-12-01

Phase III

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

  • Condition/Disease

    Recurrent or Progressive Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

2016-01-06 - 2024-01-24

Phase III

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

  • Condition/Disease

    Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus

  • Test Drug

    KEYTRUDA

Participate Sites
3Sites

Terminated3Sites

2015-09-01 - 2019-12-31

Phase III

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-06-22 - 2021-12-23

Phase III

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects

  • Condition/Disease

    HIV-1 Infection

  • Test Drug

    MK1439A

Participate Sites
6Sites

Terminated6Sites

2014-12-01 - 2017-06-30

Phase III

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection in the Asia Pacific

  • Condition/Disease

    Chronic HCV GT 1, GT 4 and GT 6 Infection

  • Test Drug

    MK-5172A

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

1 124 125 126 127 128 162
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB